Condition: B-cell Acute Lymphoblastic Leukemia · Sponsor: Merck Sharp & Dohme LLC
Researchers are looking for new ways to treat people with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) that is CD19 positive using a medicine called MK-1045. MK-1045 is an immunotherapy, which is a treatment that helps the immune system fight cancer. This trial will compare MK-1045 to a standard immunotherapy called blinatumomab. The goals of this trial are to learn if more people who receive MK-1045 have no cancer cells in their bone marrow compared to people who receive blinatumomab and if people who receive MK-1045 live longer compared to people who receive blinatumomab.
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| Rigshospitalet ( Site 0802) | Copenhagen, Capital Region, Denmark | Recruiting |
| Aarhus Universitetshospital. Hæmatologisk afdeling ( Site 0804) | Aarhus Nord, Central Jutland, Denmark | Recruiting |
| Odense Universitetshospital ( Site 0801) | Odense, Region Syddanmark, Denmark | Recruiting |
| Rambam Health Care Campus ( Site 0903) | Haifa, Israel | Recruiting |
| Haddasah Medical Center ( Site 0900) | Jerusalem, Israel | Recruiting |
| Sheba Medical Center ( Site 0902) | Ramat Gan, Israel | Recruiting |
| Sourasky Medical Center. ( Site 0904) | Tel Aviv, Israel | Recruiting |
| Policlinico Universitario Agostino Gemelli ( Site 1003) | Rome, Roma, Italy | Recruiting |
| Tokyo Metropolitan Komagome Hospital ( Site 2106) | Bunkyo, Tokyo, Japan | Recruiting |
| Radboud UMC ( Site 2003) | Geert Grooteplein-Zuid 8, Gelderland, Netherlands | Recruiting |
| HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 3009) | Madrid, Spain | Recruiting |
| Hospital Universitario de Salamanca ( Site 3002) | Salamanca, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07570173